Startup · $20m raised
Programs: Brandon BioCatalyst (CUREator)
Every investor coverage indicates participated in a round George Medicines raised.
| Investor | Rounds | Invested |
|---|---|---|
| Brandon BioCatalyst | Accelerator | - |
| George Health | Unnamed stage | - |
| Medical Research Commercialisation Fund (MRCF) | Unnamed stage | $20,000,000 |
Investors whose own portfolio pages list George Medicines, even though we haven't found any coverage of the round yet.
| Investor | Listed on |
|---|---|
| Brandon Capital | its portfolio page ↗ |
Companies George Medicines acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming George Medicines. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Brandon Capital has completed a A$439 million final close for its sixth life sciences fund, bringing the National Reconstruction Fund Corporation and WA Government in alongside backers such as HESTA, Hostplus, CSL and QIC.
Brandon BioCatalyst's CUREator incubator names its first-round awardees, distributing government-backed funding across 23 Australian life science companies working on treatments from schizophrenia to diabetes, with round two applications now open.
The CUREator incubator, run by Brandon BioCatalist's partner organisation, names its first-round awardees, distributing government-backed grant funding across 23 Australian life science companies developing treatments for diseases including diabetes, cancer and COPD.
George Medicines, a George Institute spin-out developing combination blood pressure therapies, has appointed former CSL Behring chief medical officer Dr Charmaine Gittleson as an independent non-executive director as its drug GMRx2 enters Phase III trials.
Drug developer George Medicines has added Dr Charmaine Gittleson to its board as an independent non-executive director, bringing pharma and CSL Behring leadership experience as its hypertension candidate GMRx2 advances through Phase III trials.
George Medicines has begun two Phase III trials testing its triple-combination pill GMRx2 as a first-line hypertension treatment, with patient availability possible by 2023 pending US regulatory approval.
Drug developer George Medicines has started two Phase III trials of its GMRx2 triple-combination pill as a first-line hypertension therapy, enrolling patients across seven countries, with possible availability by 2023 pending US regulator approval.
Drug developer George Medicines has named Stefan König, previously a senior Takeda executive, as its chief executive, while chief business officer Karl Roberts moves into the chief operating officer role.
George Medicines has named Stefan König, previously a Takeda franchise head, as its new CEO, while Karl Roberts moves from Chief Business Officer to Chief Operating Officer. The company also announced US FDA clearance to begin Phase III trials of GMRx2.
Index of the venture firm's portfolio updates: financing rounds for AdvanCell and ENA Respiratory, grant awards via incubator programs, two closes of Fund Six, board hires, and Myricx Bio's completed sale to Novartis.
Also Brandon BioCatalyst portfolio·Brandon Capital portfolio·Uniseed·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Cut Through Venture·SmartCompany·AFR Technology·Startup Daily·Startup Daily·SmartCompany·Startup Daily·Startup Daily·Startup Daily·@AuManufacturing·finance.yahoo.com·enarespiratory.com·Mirage News·Forbes Australia·advancell.com.au·Forbes Australia·datapile.co·Dealroom·Forbes Australia·datapile.co·Biotech Dispatch·fundedstartupsdaily.com·fundedstartupsdaily.com·Forbes Australia
The George Institute's commercial arm and its drug development company have secured $53 million from three Australian investors to speed commercialisation of medical research, with Brandon Capital's Ingmar Wahlqvist involved.